Brief: Kintor Pharma Announces Positive Early Stage Study Results Of Topical Use Compound

Kintor Pharmaceutical

10/02/2023 13:32

Feb 10 (Reuters) - Kintor Pharmaceutical Ltd  9939.HK :
    * KINTOR PHARMA ANNOUNCES POSITIVE TOP-LINE U.S. PHASE I
TRIAL
RESULTS OF GT20029, THE WORLD'S FIRST TOPICAL USE PROTAC
COMPOUND
    * KINTOR PHARMACEUTICAL LTD - DATA SHOWED GT20029 WAS SAFE,
WELL
TOLERATED
    * KINTOR PHARMACEUTICAL LTD - NO TREATMENT-EMERGENT ADVERSE
EVENTS
(TEAES) RELATED TO GT20029 IN SAD STAGE WERE REPORTED
    * KINTOR PHARMACEUTICAL LTD -  GT20029 HAD GOOD
PHARMACOKINETIC
CHARACTERISTICS IN HEALTHY SUBJECTS,  SUBJECTS WITH ANDROGENETIC
ALOPECIA OR ACNE
    * KINTOR PHARMACEUTICAL LTD - NO SERIOUS ADVERSE EVENTS WERE
REPORTED

Source text for Eikon:  ID:nPnSF170a 
Further company coverage:  9939.HK 
 ((Reuters.Briefs@thomsonreuters.com;))